Cutting-edge artificial intelligence (AI) models are transforming cancer diagnostics and treatment monitoring across multiple indications. The NeoPred AI system integrates dual-phase CT imaging and clinical data to non-invasively predict pathological responses in non-small cell lung cancer (NSCLC) patients receiving neoadjuvant chemo-immunotherapy, facilitating earlier treatment adjustments. Separately, a collaboration between CCNY and Memorial Sloan Kettering Cancer Center has developed an interpretable, open-source deep learning tool capable of precise breast cancer detection and localization in MRI scans, enhancing diagnostic accuracy and transparency in oncological imaging. These advances demonstrate AI’s growing influence in personalized oncology care and improved clinical decision-making.